LPCN

Lipocine Inc

LPCN, USA

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

https://www.lipocine.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LPCN
stock
LPCN

Lipocine Showcases LPCN 2101 at Epilepsy Meeting TipRanks

Read more →
LPCN
stock
LPCN

Lipocine Announces Positive Interim Results for PPD Trial TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$6.875

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.24

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-22.53 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-19.83 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,605.94 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.14

Low 1

High 0.3

Investors

* Institutions hold a combined 15.87% of the total shares of Lipocine Inc

1.

Vanguard Group Inc

(4.1497%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.6347%)

since

2025/07/31

3.

BlackRock Inc

(1.6474%)

since

2025/06/30

4.

Geode Capital Management, LLC

(1.1271%)

since

2025/06/30

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9417%)

since

2025/07/31

6.

Susquehanna International Group, LLP

(0.8492%)

since

2025/06/30

7.

Renaissance Technologies Corp

(0.6421%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.5415%)

since

2025/07/31

9.

Dimensional Fund Advisors, Inc.

(0.4403%)

since

2025/06/30

10.

State Street Corp

(0.3437%)

since

2025/06/30

11.

Northern Trust Corp

(0.2428%)

since

2025/06/30

12.

Extended Equity Market Fund K

(0.2301%)

since

2025/06/30

13.

Barclays PLC

(0.1737%)

since

2025/06/30

14.

Fidelity Total Market Index

(0.1613%)

since

2025/07/31

15.

Dimensional US Targeted Value ETF

(0.15%)

since

2025/08/29

16.

Spartan Extended Market Index Pool F

(0.1475%)

since

2025/07/31

17.

Fidelity Series Total Market Index

(0.1434%)

since

2025/07/31

18.

NT Ext Equity Mkt Idx Fd - L

(0.1415%)

since

2025/06/30

19.

Northern Trust Extended Eq Market Idx

(0.1415%)

since

2025/06/30

20.

Blackrock US Eq Mkt Fund CF

(0.1286%)

since

2025/07/31

21.

DFA US Targeted Value I

(0.1277%)

since

2025/07/31

22.

U.S. Equity Market Fund F

(0.1107%)

since

2025/06/30

23.

NT Ext Equity Mkt Idx Fd - NL

(0.0928%)

since

2025/06/30

24.

T. Rowe Price U.S. Equities Tr

(0.0889%)

since

2025/06/30

25.

Fidelity Nasdaq Composite Index

(0.0823%)

since

2025/07/31

26.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0814%)

since

2024/12/31

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.072%)

since

2025/06/30

28.

Schwab Total Stock Market Index

(0.0543%)

since

2025/07/31

29.

Spartan Total Market Index Pool G

(0.0506%)

since

2025/07/31

30.

Bank of America Corp

(0.0477%)

since

2025/06/30

31.

Advisor Group Holdings, Inc.

(0.0422%)

since

2025/06/30

32.

Tower Research Capital LLC

(0.0124%)

since

2025/06/30

33.

Morgan Stanley - Brokerage Accounts

(0.0106%)

since

2025/06/30

34.

UBS Group AG

(0.0088%)

since

2025/06/30

35.

CALDWELL SUTTER CAPITAL INC

(0.0087%)

since

2025/06/30

36.

Group One Trading, LP

(0.003%)

since

2025/06/30

37.

SBI Securities Co Ltd

(0.0012%)

since

2025/06/30

38.

Tidemark LLC

(0.0011%)

since

2025/06/30

39.

FMR Inc

(0%)

since

2025/06/30

40.

JPMorgan Chase & Co

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.59

EPS Estimate

-0.54

EPS Difference

-0.05

Surprise Percent

-9.2593%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.